Parecoxib

Immunotag™ Human COX-2 (Cyclooxygenase-2) ELISA

InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2.

InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2.

InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2.

InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2.

InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2.

Biochem/physiol Actions Parecoxib sodium is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor. It is a water-soluble and injectable prodrug of valdecoxib.

Biochem/physiol Actions Parecoxib sodium is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor. It is a water-soluble and injectable prodrug of valdecoxib.

Paridiprubart (anti-TLR4) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart (anti-TLR4) has the potential for the research of rheumatoid arthritis.

Paridiprubart (anti-TLR4) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart (anti-TLR4) has the potential for the research of rheumatoid arthritis.

Paridiprubart (anti-TLR4) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart (anti-TLR4) has the potential for the research of rheumatoid arthritis.

Paridiprubart (anti-TLR4) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart (anti-TLR4) has the potential for the research of rheumatoid arthritis.